ADAMs in cancer cell proliferation and progression

被引:449
作者
Mochizuki, Satsuki [1 ]
Okada, Yasunori [1 ]
机构
[1] Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan
关键词
MESSENGER-RNA EXPRESSION; ALPHA-CONVERTING ENZYME; EPIDERMAL-GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; L1 ADHESION MOLECULE; CYSTEINE-RICH DOMAIN; 12 MELTRIN ALPHA; METALLOPROTEASE-DISINTEGRIN; BREAST-CANCER; MATRIX METALLOPROTEINASES;
D O I
10.1111/j.1349-7006.2007.00434.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A disintegrin and metalloproteinases (ADAMs) are a new gene family of proteins with sequence similarity to the reprolysin family of snake venomases that share the metalloproteinase domain with matrix metalloproteinases (MMPs). They are structurally classified into two groups: the membrane-anchored ADAM and ADAM with thrombospondin motifs (ADAMTS). These molecules are involved in various biological events such as cell adhesion, cell fusion, cell migration, membrane protein shedding and proteolysis. Studies on the biochemical characteristics and biological functions of ADAMs are in progress, and accumulated lines of evidence have shown that some ADAMs are expressed in malignant tumors and participate in the pathology of cancers. The activities of ADAMs are regulated by gene expression, intracytoplasmic and pericellular regulation, activation of the zymogens and inhibition of activities by inhibitors. Many ADAM species, including ADAM8, ADAM9, ADAM10, ADAM12, ADAM15, ADAM17, ADAM19, ADAM28, ADAMTS1, ADAMTS4 and ADAMTS5, are expressed in human malignant tumors. Many of them are involved in the regulation of growth factor activities and integrin functions, leading to promotion of cell growth and invasion, although the precise mechanisms of these are not clear at the present time. In this article, we review recent information about ADAM family members and their implications for cancer cell proliferation and progression.
引用
收藏
页码:621 / 628
页数:8
相关论文
共 80 条
[1]   The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3 [J].
Amour, A ;
Knight, CG ;
Webster, A ;
Slocombe, PM ;
Stephens, PE ;
Knäuper, V ;
Docherty, AJP ;
Murphy, G .
FEBS LETTERS, 2000, 473 (03) :275-279
[2]   The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs [J].
Amour, A ;
Knight, CG ;
English, WR ;
Webster, A ;
Slocombe, PM ;
Knäuper, V ;
Docherty, AJP ;
Becherer, JD ;
Blobel, CP ;
Murphy, G .
FEBS LETTERS, 2002, 524 (1-3) :154-158
[3]   Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy [J].
Asakura, M ;
Kitakaze, M ;
Takashima, S ;
Liao, Y ;
Ishikura, F ;
Yoshinaka, T ;
Ohmoto, H ;
Node, K ;
Yoshino, K ;
Ishiguro, H ;
Asanuma, H ;
Sanada, S ;
Matsumura, Y ;
Takeda, H ;
Beppu, S ;
Tada, M ;
Hori, M ;
Higashiyama, S .
NATURE MEDICINE, 2002, 8 (01) :35-40
[4]   Metalloproteinase inhibitors: biological actions and therapeutic opportunities [J].
Baker, AH ;
Edwards, DR ;
Murphy, G .
JOURNAL OF CELL SCIENCE, 2002, 115 (19) :3719-3727
[5]   ADAM15 decreases integrin αvβ3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion [J].
Beck, V ;
Herold, H ;
Benge, A ;
Luber, B ;
Hutzler, P ;
Tschesche, H ;
Kessler, H ;
Schmitt, M ;
Geppert, HG ;
Reuning, U .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2005, 37 (03) :590-603
[6]   Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells [J].
Blanchot-Jossic, F ;
Jarry, A ;
Masson, D ;
Bach-Ngohou, K ;
Paineau, J ;
Denis, MG ;
Laboisse, CL ;
Mosnier, JF .
JOURNAL OF PATHOLOGY, 2005, 207 (02) :156-163
[7]   TACE is required for the activation of the EGFR by TGF-α in tumors [J].
Borrell-Pagès, M ;
Rojo, F ;
Albanell, J ;
Baselga, J ;
Arribas, J .
EMBO JOURNAL, 2003, 22 (05) :1114-1124
[8]  
Carl-McGrath S, 2005, INT J ONCOL, V26, P17
[9]   Catalytic properties of ADAM19 [J].
Chesneau, V ;
Becherer, JD ;
Zheng, YF ;
Erdjument-Bromage, H ;
Tempst, P ;
Blobel, CP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (25) :22331-22340
[10]   Extracellular signal-regulated kinase phosphorylates tumor necrosis factor α-converting enzyme at threonine 735:: A potential role in regulated shedding [J].
Díaz-Rodríguez, E ;
Montero, JC ;
Esparís-Ogando, A ;
Yuste, L ;
Pandiella, A .
MOLECULAR BIOLOGY OF THE CELL, 2002, 13 (06) :2031-2044